Find Clinical Trial

Home » Find Clinical Trials » Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os) and rosiglitazone (4 to 8 mg daily per os) given in combination with metformin in type 2 diabetic patients.A 2-year international, multicentre, randomised, double-blind, parallel-group study followed by a 2-year double blind extension. – ENDORSE

Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os) and rosiglitazone (4 to 8 mg daily per os) given in combination with metformin in type 2 diabetic patients.A 2-year international, multicentre, randomised, double-blind, parallel-group study followed by a 2-year double blind extension. – ENDORSE

← Back

Study Phase	Phase 3

Therapeutic Area	Metabolism

Indication	Diabetes - Type II

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	GLICLAZIDE, S005702

Active Substance Code	S005702

Protocol Code	CL3-05702-013

EudraCT Code	2006-001240-30

ISRCTN Code	ISRCTN67790431

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.